Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

Korábbi kezelés

• Patients must not be pregnant. All premenopausal patients will undergo pregnancy testing. Men will agree to not father a child while on protocol treatment. Men and women will practice effective birth control while receiving protocol treatment.
• Participants may not be receiving any other Non-FDA approved study agents at the start of vaccination
• Autoimmune or inflammatory disorders requiring active treatment with systemic steroids or immunosuppressive therapy limited to the following:
  • GI Disorders: (including inflammatory bowel disease [e.g., ulcerative colitis, Crohn's disease]
  • Systemic lupus erythematosus
  • Wegener's syndrome [granulomatosis with polyangiitis]
  • Myasthenia gravis
  • Graves' disease
  • Rheumatoid arthritis
  • Hypophysitis
  • Uveitis

Más betegség

• Because of compromised cellular immunity, patients with a known history of HIV are excluded
• Uncontrolled intercurrent illness including uncontrolled active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements.

Egyéb

• Leukemia with active CNS involvement

• Patients with AML who have undergone AML cell harvest and cryopreservation as per protocol 16-593 or companion protocol 18-232.
• Patients must have had a minimum of 5x107 cells cryopreserved.
• Patients must be day 25-45 following allogeneic transplantation from either:
  • Group A: HLA 8/8 or 7/8 matched related donor or HLA 8/8 matched unrelated donor, as determined by antigen or allele level typing at HLA A,B,C, and HLA DRB1.
  • OR
• Group B: Haplo-identical donor
  • Patients must be ≥ 18 years old
  • ECOG performance status ≤2 (Appendix A)
  • Participants must have normal organ and marrow function as defined below:
• Total bilirubin ≤ 2.0 mg/dL (unless patient has Gilbert's disease)
• AST(SGOT)/ALT(SGPT) ≤ 3 × institutional upper limit of normal
• Creatinine ≤ 2.0 mg/dl
• Absolute neutrophil count > 1000
• Platelet count > 50,000
  • The effects of DC/AML fusion cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  • No evidence of ongoing grade 2 or higher aGVHD
  • Must be on prednisone <20mg or other steroid equivalent
  • Donor chimerism of bone marrow >60%
  • Resolution of all transplant related grade III-IV toxicity as per CTC criteria 4.0
  • Complete remission defined by absence of circulating blasts and less than 5% blasts in the bone marrow
  • Ability to understand and the willingness to sign a written informed consent document.
  • Eligibility Prior to Initiating Vaccination (Groups A and B)
• Assessments to be done between Day 45-75 post-transplant.
• At least 2 doses of fusion vaccine were produced
• No ongoing grade II-IV acute GVHD
• Prednisone requirement of < 20mg a day or steroid equivalent
• Participants must have normal organ and marrow function as defined below:
  • Total bilirubin ≤ 2.0 mg/dL (unless patient has Gilbert's disease)
  • AST(SGOT)/ALT(SGPT) ≤ 3 × institutional upper limit of normal
  • Creatinine ≤ 2.0 mg/dl
  • Absolute neutrophil count > 1000
  • Platelet count > 50,000
• No uncontrolled acute infection
• No CTCAE grade ≥ 3 non-hematologic toxicity
• No serious intercurrent illness such as active acute infection, or significant cardiac disease characterized by clinically significant arrhythmia, active ischemic coronary disease or symptomatic congestive heart failure.
• Participants must be in a complete remission
  • Pre-Treatment Criteria Prior to Decitabine (Group A Cohort 2)
• Assessments to be done within 3 days prior to initiation of therapy.
• Participants must have normal organ and marrow function as defined below:
• Total bilirubin ≤ 2.0 mg/dL (unless patient has Gilbert's disease)
  • AST(SGOT)/ALT(SGPT) ≤ 3 × institutional upper limit of normal
  • Creatinine ≤ 2.0 mg/dl
  • Absolute neutrophil count > 1000
  • Platelet count > 50,000